Consequently, algorithms for the use of medical therapy have been developed in recent years for the treatment of T2D based on individualized cardiovascular risk profiles with sodium glucose cotransporter 2 inhibitors (SGLT2is) being recommended mainly for individuals with congestive heart failure, established ASCVD or high cardiovascular risk (16–19). Here, SLC5A2 is linked to type 2 diabetes mellitus.